Trauma rarely travels alone. For many veterans, post-traumatic stress and substance use don’t arrive as separate struggles — they intertwine, each one making the other harder to treat. For decades, this overlap has been one of the most stubborn challenges in veteran mental health care, with most studies and treatments designed to address only one issue at a time. This summer, that pattern began to shift, as one of the country’s largest health systems opened the door to a treatment combination it had never formally studied before.
WHAT HAPPENED
In June 2026, the Department of Veterans Affairs announced a new placebo-controlled clinical trial evaluating MDMA-assisted therapy for veterans living with both PTSD and alcohol use disorder. The study will enroll roughly 80 veterans at the VA Providence Healthcare System in Rhode Island. VA Secretary Doug Collins noted that MDMA may help expand the toolkit available for treating veterans’ most severe mental health disorders, while Health and Human Services Secretary Robert F. Kennedy Jr. stated that the agency is prioritizing breakthrough-designated therapies, including psychedelic treatments, to address the country’s mental health crisis. The Disabled American Veterans organization (DAV) publicly applauded the trial, noting that many veterans have exhausted traditional treatment options without relief. This marks the VA’s first formal study combining MDMA-assisted therapy with treatment for co-occurring alcohol use disorder — a population historically excluded from many psychedelic therapy trials.
THE SCIENCE PERSPECTIVE
Previous Phase 3 trials of MDMA-assisted therapy for PTSD alone found striking results: participants experienced significantly greater reductions in PTSD symptoms compared to therapy combined with a placebo, with response rates of roughly 86.5 percent versus 69 percent at eighteen weeks. MDMA appears to work, in part, by reducing activity in the amygdala — the brain’s fear-processing center — while increasing the availability of serotonin and oxytocin, creating a window in which traumatic memories can be discussed with less overwhelming emotional intensity.
What makes this new VA trial distinct is its focus on a population that combines PTSD with alcohol use disorder, two conditions that frequently occur together and historically complicate treatment for each other. Addressing both simultaneously, rather than sequentially, reflects a more realistic clinical picture of how trauma and substance use actually show up in veterans’ lives — and tests whether MDMA-assisted therapy’s trauma-processing window can support recovery from both conditions at once.
DID YOU KNOW?
In earlier Phase 3 clinical trials, MDMA-assisted therapy produced an 86.5% treatment response rate compared to 69% for therapy paired with a placebo — one of the largest effect sizes recorded in PTSD treatment research.
THE DSS PERSPECTIVE
There is something significant in watching a major institution choose to study complexity rather than avoid it. Veterans carrying both trauma and substance use have too often been treated as too complicated, too high-risk, or simply outside the scope of promising new therapies. This trial says otherwise. It reflects a core DSS conviction: that transformation isn’t found in the substance alone, but in the structured, supported container around it — therapy, preparation, integration, and time. MDMA here is not positioned as an escape from difficulty, but as a tool that may help create the internal safety necessary to finally turn toward it, with trained support close by. That distinction matters enormously, both clinically and spiritually.
WHY THIS MATTERS
This trial signals a broader shift in how federal institutions are willing to approach the realities of trauma and addiction together, rather than as separate silos. If successful, it could influence VA-wide protocols and inform how psychedelic-assisted therapies are eventually studied for other high-complexity populations. For veterans who have long felt unseen by treatment systems built around simpler diagnostic categories, this represents a meaningful step toward care that meets them where they actually are.
“What changes when an institution chooses to meet complicated pain with curiosity instead of exclusion?”
THE DSS REFLECTION
Watching a system like the VA take on this kind of study is a small but meaningful marker of collective evolution. For so long, the structure of mental health care has asked people to fit their suffering into clean, separate categories — trauma here, addiction there — when lived human experience rarely organizes itself so neatly. This trial is an acknowledgment that healing, like consciousness itself, doesn’t move in straight lines.
As psychedelic-assisted therapies continue to move through rigorous federal research channels, we have an opportunity to watch institutional trust be rebuilt in real time — not through grand promises, but through careful, methodical study of exactly the populations who need it most. This is what responsible expansion of consciousness medicine looks like: not casual access, but deliberate, supported, and scientifically grounded care extended to those who have been waiting longest. The work ahead is not only pharmacological. It’s relational, communal, and institutional — building the kind of trust that allows people to bring their whole, complicated selves into the room and be met with care rather than judgment.
Looking to explore more? Our Knowledge Library contains dozens of additional articles, resources, and educational content. You can browse it anytime HERE!
REFERENCES
1. Glenn M. VA rolling out study of MDMA therapy for veterans with PTSD. Washington Times. June 16, 2026. Accessed June 19, 2026. https://www.washingtontimes.com/news/2026/jun/16/va-rolling-study-mdma-therapy-veterans-ptsd/
2. Disabled American Veterans. DAV applauds VA’s study on MDMA for PTSD and alcoholism. Published May 28, 2026. Accessed June 19, 2026.https://www.dav.org/learn-more/news/2026/dav-applauds-vas-study-on-mdma-for-ptsd-and-alcoholism/
3. Mitchell JM, Ot’alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. doi:10.1038/s41591-023-02565-4